Cetuximab disappoints in colon cancer

9 June 2010 | by Nicola Garrett Print this article Comments Share this article
The addition of cetuximab to standard adjuvant chemotherapy with FOLFOX does not extend disease free survival or overall survival for patients with stage III colon cancer with wild-type KRAS, a phase III study finds....

Want to read complete article? Please Sign in or Register.

Most viewed articles this week

Recent comments

Related sites